drugset / Trial / NCT00215254

Quetiapine in Social Anxiety Disorder

NCT00215254

Phase 2/3 Completed 15 enrolled Duke University AstraZeneca · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of the study is to examine the effectiveness and tolerability of quetiapine for the treatment of social anxiety disorder (SAD). The hypothesis is that quetiapine will be effective and well-tolerated for patients with social anxiety disorder.

Timeline

Start
2004-03
Primary completion
Completion
2006-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Quetiapine Small molecule 100 mg
Subject Quetiapine Small molecule 400 mg

Indications